...
首页> 外文期刊>International Urology and Nephrology >Improvement in uremic symptoms after increasing daily dialysate volume in patients on chronic peritoneal dialysis with declining renal function.
【24h】

Improvement in uremic symptoms after increasing daily dialysate volume in patients on chronic peritoneal dialysis with declining renal function.

机译:慢性腹膜透析患者肾功能下降时,每天增加透析液量后尿毒症症状得到改善。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Patients on peritoneal dialysis (PD) can develop uremic symptoms as their residual renal function declines. In this retrospective study, we assessed the effect of increasing the dose of dialysis in patients who developed uremic symptoms. METHODS: Patients on PD who had an increase in their dialysis dose due to either the appearance of uremic symptoms or to worsening biochemical parameters were included in this study. These patients had to have been on PD for at least 6 months before and after the increase in their dialysis dose. Patients whose dialysis dose was increased after the initial Adequest (done within 2-3 months of starting PD) findings or for reasons other than underdialysis were excluded from this study. The symptoms studied in 104 patients included fatigue, anorexia, insomnia, pruritus and nausea. The presence or absence of theses symptoms was evaluated before and after the increase in the dialysis volume. Several clinical and laboratory data including the adequacy results were compared before and after the increase in dialysis dose. RESULTS: Patients were on PD for 24.6+/-16 months when dialysis dose was increased. Eighty-five (82%) of them were on continuous ambulatory peritoneal dialysis (CAPD) while the remaining were on continuous cycler peritoneal dialysis (CCPD). Fatigue was the most common symptom that led to an increase in the dialysis dose (64%). The prevalence of all the symptoms studied decreased significantly after the increase in dose of dialysis. The weekly peritoneal creatinine clearance increased from 47.35+/-0.88 to 57.34+/-1.401 (P < 0.0001) and the weekly Kt/V increased from 1.8+/-0.03 to 2.27+/-0.05 (P < 0.0001). The daily urine volume and the residual GFR decreased from 318.7+/-36.4 to 151.9+/-22.8 ml/day (P < 0.0001) and 2.05+/-0.2 to 0.82+/-0.12 ml/min (P < 0.0001) respectively during the study period. CONCLUSION: The prevalence of all uremic symptoms decreased significantly after the daily dialysate volume was increased. The improvement in symptoms despite the decline in residual function emphasizes the beneficial effect of increased dialysate volume, which produced a significantly higher peritoneal creatinine clearance and Kt/V after the change in the PD prescription.
机译:目的:腹膜透析(PD)患者的残余肾功能下降会出现尿毒症症状。在这项回顾性研究中,我们评估了增加尿毒症症状患者透析剂量的效果。方法:本研究包括因尿毒症症状或生化指标恶化而导致透析剂量增加的PD患者。这些患者在增加透析剂量前后必须接受PD至少6个月。最初的Adequest(开始PD后2-3个月内完成)发现或由于除透析不足以外的原因导致透析剂量增加的患者被排除在本研究之外。在104位患者中研究的症状包括疲劳,厌食,失眠,瘙痒和恶心。在透析体积增加之前和之后评估这些症状的存在与否。在增加透析剂量之前和之后,比较了包括充分性结果在内的一些临床和实验室数据。结果:当透析剂量增加时,患者接受PD治疗24.6 +/- 16个月。其中八十五(82%)名患者接受非卧床连续性腹膜透析(CAPD),其余者接受连续循环腹膜透析(CCPD)。疲劳是导致透析剂量增加的最常见症状(64%)。透析剂量增加后,所有研究症状的患病率均明显降低。每周腹膜肌酐清除率从47.35 +/- 0.88增加到57.34 +/- 1.401(P <0.0001),每周Kt / V从1.8 +/- 0.03增加到2.27 +/- 0.05(P <0.0001)。每日尿量和残余GFR分别从318.7 +/- 36.4降至151.9 +/- 22.8 ml / min(P <0.0001)和2.05 +/- 0.2降至0.82 +/- 0.12 ml / min(P <0.0001)在学习期间。结论:每日透析液量增加后,所有尿毒症症状的发生率均明显降低。尽管残留功能下降,但症状的改善强调了透析液体积增加的有益效果,这在更改PD处方后产生了明显更高的腹膜肌酐清除率和Kt / V。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号